Compare TRVI & CET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TRVI | CET |
|---|---|---|
| Founded | 2011 | 1929 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | 2019 | N/A |
| Metric | TRVI | CET |
|---|---|---|
| Price | $12.62 | $50.53 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $20.59 | N/A |
| AVG Volume (30 Days) | ★ 2.4M | 48.9K |
| Earning Date | 11-13-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.54% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 7.40 |
| Revenue | N/A | ★ $27,062,484.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $6.84 |
| Revenue Growth | N/A | ★ 15.78 |
| 52 Week Low | $3.43 | $40.24 |
| 52 Week High | $14.39 | $52.44 |
| Indicator | TRVI | CET |
|---|---|---|
| Relative Strength Index (RSI) | 52.54 | 54.93 |
| Support Level | $12.92 | $49.91 |
| Resistance Level | $14.39 | $50.95 |
| Average True Range (ATR) | 0.87 | 0.66 |
| MACD | -0.09 | 0.14 |
| Stochastic Oscillator | 43.71 | 80.80 |
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
Central Securities Corp is a non-diversified closed-end management investment company. Its investment objective is long-term growth of capital. The company invests in common stocks, bonds, convertible bonds, preferred stocks, convertible preferred stocks, warrants, options real estate, or short-term obligations of governments, banks, and corporations.